.

LPL - PSC KINGSWAY CAMP HOME VISIT

SHOP NO-70, GF, MALL ROAD, KINSWAY
CAMP, GTB HUDSON LANE
DELHI

Name : Mr. TENZIN DORJE Collected : 28/10/2016 11:20:00AM

Received : 28/10/2016 11:21:04AM
Lab No. : 133131590 Age: 43 Years Gender: Male Reported : 29/10/2016 5:07:09PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

CREATININE, SERUM 0.79 mg/dL 0.67 - 1.17
(Compensated Jaffe's reaction, IDMS traceable)

SODIUM, SERUM 138.00 mEq/L 136.00 - 146.00

(Indirect ISE)

POTASSIUM, SERUM 4.16 mEq/L 3.50 - 5.10

(Indirect ISE)

IRON STUDIES, SERUM

(Spectrophotometry)

Iron 210.00 µg/dL 65.00 - 175.00

Total Iron Binding Capacity 417.00 µg/dL 250.00 - 425.00
Transferrin Saturation 50.36 % 20.00 - 50.00

Comments
Iron is an essential trace mineral element which forms an important component of hemoglobin,
metallocompounds and Vitamin A. Deficiency of iron, leads to microcytic hypochromic anemia. The toxic
effects of iron are deposition of iron in various organs of the body and hemochromatosis.
Total Iron Binding capacity (TIBC) is a direct measure of the protein Transferrin which transports iron from
the gut to storage sites in the bone marrow. In iron deficiency anemia, serum iron is reduced and TIBC
increases.
Transferrin Saturation occurs in Idiopathic hemochromatosis and Transfusional hemosiderosis where no
unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital
deficiency of Transferrin.

THYROID PROFILE, FREE, SERUM

(CLIA)

T3, Free; FT3 2.71 pg/mL 2.30 - 4.20

T4, Free; FT4 1.05 ng/dL 0.89 - 1.76
TSH, Ultrasensitive 3.577 uIU/mL 0.550 - 4.780

Note
1. TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a
minimum between 6-10 pm. The variation is of the order of 50%. hence time of the day has influence
on the measured serum TSH concentrations.

2. TSH Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in
some individuals

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*133131590* Page 1 of 6
.

LPL - PSC KINGSWAY CAMP HOME VISIT

SHOP NO-70, GF, MALL ROAD, KINSWAY
CAMP, GTB HUDSON LANE
DELHI

Name : Mr. TENZIN DORJE Collected : 28/10/2016 11:20:00AM

Received : 28/10/2016 11:21:04AM
Lab No. : 133131590 Age: 43 Years Gender: Male Reported : 29/10/2016 5:07:09PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

Clinical Use
· Primary Hypothyroidism
· Hyperthyroidism
· Hypothalamic - Pituitary hypothyroidism
· Inappropriate TSH secretion
· Nonthyroidal illness
· Autoimmune thyroid disease
· Pregnancy associated thyroid disorders
· Thyroid dysfunction in infancy and early childhood

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*133131590* Page 2 of 6
.

LPL - PSC KINGSWAY CAMP HOME VISIT

SHOP NO-70, GF, MALL ROAD, KINSWAY
CAMP, GTB HUDSON LANE
DELHI

Name : Mr. TENZIN DORJE Collected : 28/10/2016 11:20:00AM

Received : 28/10/2016 11:21:04AM
Lab No. : 133131590 Age: 43 Years Gender: Male Reported : 29/10/2016 5:07:14PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

LIPID PROFILE, COMPLETE, SERUM
(Spectrophotometry, Agarose gel Electrophoresis)

Sample Appearance Clear

Cholesterol Total 154.00 mg/dL <200.00

Triglycerides 90.00 mg/dL <150.00

HDL Cholesterol 53.00 mg/dL >40.00

LDL Cholesterol 83.00 mg/dL <100.00
VLDL Cholesterol 18.00 mg/dL <30.00
Non HDL Cholesterol 101.00 mg/dL <130.00
Cholesterol:HDL Ratio 2.91 3.30 - 4.40

Lipoprotein Electrophoresis .

HDL 28.70 % 15.1 - 39.9

LDL 48.70 % 42.3 - 69.5
VLDL 22.60 % 2.0 - 31.2
Chylomicrons Absent Nil

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*133131590* Page 3 of 6
.

LPL - PSC KINGSWAY CAMP HOME VISIT

SHOP NO-70, GF, MALL ROAD, KINSWAY
CAMP, GTB HUDSON LANE
DELHI

Name : Mr. TENZIN DORJE Collected : 28/10/2016 11:20:00AM

Received : 28/10/2016 11:21:04AM
Lab No. : 133131590 Age: 43 Years Gender: Male Reported : 29/10/2016 5:07:14PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

Interpretation
-----------------------------------------------------------------------------------
| NATIONAL LIPID | TOTAL | TRIGLYCERIDE | LDL CHOLESTEROL |NON HDL |
| ASSOCIATION | CHOLESTEROL | in mg/dL | in mg/dL |CHOLESTEROL |
| RECOMMENDATIONS | in mg/dL | | |in mg/dL |
| (NLA-2014) | | | | |
|-------------------|---------------|--------------|-----------------|--------------|
| Optimal | <200 | <150 | <100 | <130 |
|-------------------|---------------|--------------|-----------------|--------------|
| Above Optimal | - | - | 100- 129 | 130 - 159 |
|-------------------|---------------|--------------|-----------------|--------------|
| Borderline High | 200-239 | 150-199 | 130-159 | 160 - 189 |
|-------------------|---------------|--------------|-----------------|--------------|
| High | >=240 | 200-499 | 160-189 | 190 - 219 |
|-------------------|---------------|--------------|-----------------|--------------|
| Very High | - | >=500 | >=190 | >=220 |
-----------------------------------------------------------------------------------

----------------------------------------
| REMARKS | CHOLESTEROL:HDL Ratio |
| | |
|----------------|------------------------|
| Low risk | 3.3 - 4.4 |
|----------------|------------------------|
| Average risk | 4.5 - 7.1 |
|----------------|------------------------|
| Moderate risk | 7.2 - 11.0 |
|----------------|------------------------|
| High risk | >11.0 |
-----------------------------------------

Note
1. Measurements in the same patient can show physiological& analytical variations. Three serial samples
1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
2. NLA-2014 identifies Non HDL Cholesterol(an indicator of all atherogenic lipoproteins such as LDL ,
VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for cholesterol
lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.
3. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have
been achieved.
4. Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered among patients
with moderate risk for ASCVD for risk refinement

Comment
A variety of genetic conditions are associated with accumulation in plasma of specific class of lipoprotein
particles. The critical first step in managing lipid disorder is to determine the class or classes of lipoprotein that
are increased or decreased in a patient. Frederickson classification can be helpful in this regard. The
hyperlipidemic status should be evaluated to determine if it is a primary lipoprotein disorder or secondary to
metabolic disease. The diagnosis of primary hyperlipidemia is made after secondary causes have been ruled
PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*133131590* Page 4 of 6
.

LPL - PSC KINGSWAY CAMP HOME VISIT

SHOP NO-70, GF, MALL ROAD, KINSWAY
CAMP, GTB HUDSON LANE
DELHI

Name : Mr. TENZIN DORJE Collected : 28/10/2016 11:20:00AM

Received : 28/10/2016 11:21:04AM
Lab No. : 133131590 Age: 43 Years Gender: Male Reported : 29/10/2016 5:07:14PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

out. It is important to diagnose primary lipid disorder since the underlying etiology has significant effect on
development of CHD, on response to drug therapy, and on the management of other family members. Type II b
is the most commonly inherited lipid disorder, occurring in approximately 1 in 200 persons. Familial
hypertriglyceridemia (FHTG) is a relatively common (1:500) autosomal dominant disorder of unknown etiology.
It is important to consider & rule out secondary causes of hypertriglyceridemia (Obesity, Type 2 DM,
Alcoholism, Renal failure, Cushing's syndrome etc.) before making the diagnosis of FHTG.

------------------------------------------------------------------------------------------------
| FREDRICKSON CLASSIFICATION |
|------------------------------------------------------------------------------------------------|
| Type of |Molecular |Estimated |Lipoprotein |Cholesterol,|Triglyceride|Serum |
|Hyperlipoproteinemia|defect |incidence |elevated |Total(mg/dL)|(mg/dL) |Appearance |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| I |Lipoprotien|1 in |Chylomicrons|+ to ++ | ++++ |Milky |
|Familial |lipase |1,000,000 | |200-400 |>3000 | |
|Chylomicronemia |deficiency;| | | | | |
|Syndrome |Apo C II | | | | | |
| |deficiency | | | | | |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| IIa |Mutation in|1 in 500 | LDL | +++ |Normal |Clear |
|Familial |LDL | | |300-1000 | | |
|Hypercholesterolemia|receptor, | | | | | |
| |Apo B 100 | | | | | |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| II b |Unknown |1 in 200 |LDL & VLDL |++ to +++ | ++ |Clear to |
|Familial Combined | | | |280-350 |200-500 |slightly |
|Hyperlipidemia | | | | | |turbid |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| III |Genetic |1 in 10,000|Chylomicron |++ to +++ |++ to +++ |Clear to |
|Familial Dysbeta |variation | |and VLDL |300- 500 |200- 900 |slightly |
|lipoproteinemia or |in APO E | |remnant | | |turbid |
|Familial broadbeta | | | (IDL) | | | |
|disease | | | | | | |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| IV |Unknown |1 in 500 | VLDL |Usually | ++ |Turbid |
|Familial | | | |<270 |200-1000 | |
|hypertriglyceridemia| | | | | | |
|--------------------|-----------|-----------|------------|------------|------------|------------|
| V |Unknown |1 in 500 |Chylomicron |++ to +++ | ++++ |Milky |
|Familial | | |& VLDL |<500 |<3000 | |
|hypertriglyceridemia| | | | | | |
------------------------------------------------------------------------------------------------

Dr Himangshu Mazumdar Dr. Nimmi Kansal

MD (Biochemistry) MD (Biochemistry)
Consultant Biochemist HOD Biochem & IA

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*133131590* Page 5 of 6
.

LPL - PSC KINGSWAY CAMP HOME VISIT

SHOP NO-70, GF, MALL ROAD, KINSWAY
CAMP, GTB HUDSON LANE
DELHI

Name : Mr. TENZIN DORJE Collected : 28/10/2016 11:20:00AM

Received : 28/10/2016 11:21:04AM
Lab No. : 133131590 Age: 43 Years Gender: Male Reported : 29/10/2016 5:07:14PM
A/c Status : P Ref By : SELF Report Status : Final

Test Name Results Units Bio. Ref. Interval

-------------------------------End of report --------------------------------

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*133131590* Page 6 of 6